Research programme: lipoxin A4 analogues - Bayer HealthCare Pharmaceuticals

Drug Profile

Research programme: lipoxin A4 analogues - Bayer HealthCare Pharmaceuticals

Alternative Names: Lipoxin A4 analog - Bayer HealthCare Pharmaceuticals; ZK-192

Latest Information Update: 19 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Antiasthmatics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Crohn's disease

Most Recent Events

  • 04 Apr 2007 Berlex Inc has been acquired by Bayer HealthCare
  • 09 Nov 2005 Data presented at the 13th United European Gastroenterology Week (UEGW-2005) have been added to the Inflammatory bowel disorders pharmacodynamics section
  • 20 Nov 2004 Preclinical trials in Crohn's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top